Visualized UEAs in a rodent.
SonoThera is developing the world’s first ultrasound-guided nonviral gene delivery platform, which is designed to overcome the limitations of other gene therapy approaches.
The promise of gene therapy to cure diseases is falling short due to significant delivery, efficacy, and safety limitations.
Use a wide variety of nucleic acid formats to develop genetic medicines.
Address a broader variety of diseases with a cargo capacity that exceeds viral-mediated therapies.
Target a large variety of organs where systemically administered viral vectors fail to transduce tissue sufficiently and without toxicity.
Expand the patient pool that can receive gene therapies for improved outcomes.
Robust delivery to the desired cellular compartments.
Ultrasound enhancement agents have been safely used in the clinic for decades along with FDA-cleared ultrasound hardware.
Our platform uses sonoporation, a microbubble-mediated biophysical process that uses FDA-cleared ultrasound equipment and proprietary acoustic profiles to deliver payloads through a transient pore in a cell membrane.
Successful proof of concept studies and reviews on the topic of sonoporation and gene delivery.
You have selected a link to an article written and published by persons not affiliated with SonoThera, Inc. The views expressed in the article are those of the author and do not reflect the views of SonoThera, Inc. Additionally, the information contained in these articles may not be current. SonoThera, Inc. disavows any obligation to correct or to update the information contained in these articles.
